Abbott Laboratories (ABT) News
NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
99.60+1.11 (+1.13%)
At close: Oct 9, 4:02 PM ET · Delayed 15 min
ABT news summary
We found 37 recent headlines mentioning Abbott Laboratories (ABT): 11 in the past week and 28 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, ABT is up 1.13% at $99.60. The most recent story, "Cancer Stocks to Consider as Oncology Innovation Accelerates", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Abbott Laboratories headlines
- Cancer Stocks to Consider as Oncology Innovation AcceleratesOncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.NasdaqABT, PFE, MMSI, AZN
- Is it the Right Time to Hold TNDM Stock in Your Portfolio?Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.NasdaqTNDM, ABT, GMED, PAHC
- Is it the Right Time to Add Phibro Stock to Your Portfolio?PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.NasdaqPAHC, ABT, GMED, VCYT
- Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after…Nasdaq
- Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should KnowRecently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.Nasdaq
- AngioDynamics Names Honroth As CEO, Clemmer To Retire; Stock Down In Premarket(RTTNews) - Medical technology company, AngioDynamics, Inc. (ANGO) on Thursday announced the appointment of Eric Honroth as President and Chief Executive Officer (CEO) and a member of its Board of…NasdaqABT, ANGO, BDX, BSX
- Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTechSeeking AlphaABT, BCS, SYK
- Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to NoteAbbott (ABT) closed the most recent trading day at $98.16, moving 1.94% from the previous trading session.Nasdaq
- Abbott Expands CardioMEMS System With FDA-Approved Patient Monitoring Features(RTTNews) - Abbott (ABT) announced that the FDA has approved new capabilities for its CardioMEMS HF System, allowing heart failure patients in the U.S. to view key heart health measurements and…Nasdaq
- Abbott Receives FDA Approval For CardioMEMS HF System Updates(RTTNews) - Abbott Laboratories, Inc. (ABT), a healthcare company, announced Monday that the U.S. Food and Drug Administration (FDA) approved updates to the CardioMEMS HF System. The approval enables…Nasdaq
- The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health CompaniesHealthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.NasdaqABT, CORT, BHC, PGEN
- How to Create a Million-Dollar Stock PortfolioSuccessful stock investors have one thing in common: the power of compounding.NasdaqWFC, ABT, ABBV
- Rothschild & Co Upgrades Abbott Laboratories to Buy from NeutralOn October 2, 2026, Rothschild & Co upgraded their outlook for Abbott Laboratories (NYSE:ABT) (BMV:ABT) from Neutral to Buy.Abbott Laboratories, based in the United States, is a global healthcare…Nasdaq
- Notable ETF Inflow Detected - SCHD, COP, ABT, BMYLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Dividend Equity ETF (Symbol: SCHD) where we have detected…NasdaqSCHD, COP, ABT, BMY
- DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes CareDexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.NasdaqDXCM, ABT, NVO, MMED
- 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.NasdaqABT, CORT, BHC, PGEN
- These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway.Key PointsCVS, Abbott, and UnitedHealth all yield under 5%, yet Wall Street rates each a strong buy with 40%+ upside to target.NasdaqUNH, ABT, CVS
- Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?Key PointsAbbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, and nutrition.NasdaqABT, ISRG
- Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to KnowThe latest trading day saw Abbott (ABT) settling at $98.83, representing a -2.1% change from its previous close.Nasdaq
- Abbott Launches SimpleScreen CRC Blood Test For Colorectal Cancer Screening(RTTNews) - Abbott (ABT) has launched SimpleScreen CRC in the U.S., an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older who are at average risk.Nasdaq
- NVST vs. ABT: Which Stock Is the Better Value Option?NVST vs. ABT: Which Stock Is the Better Value Option?NasdaqNVST, ABT
- Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to NoteAbbott (ABT) concluded the recent trading session at $101.07, signifying a -2.34% move from its prior day's close.Nasdaq
- Abbott Laboratories: A Strong Business At A Fair PriceSeeking Alpha
- Here's Why You Should Hold Stryker Stock in Your Portfolio for NowSYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.NasdaqSYK, ABT, GMED, VCYT
- Abbott: Quality Remains, But Exact Sciences Has Raised The Bar For BuySeeking Alpha
- Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.NasdaqBSX, ABT, GMED
- Daily Dividend Report: PCAR,ABT,TXN,MCD,CLPACCAR's Board of Directors declared a regular quarterly cash dividend of thirty-five cents per share, payable on December 2, 2026, to stockholders of record at the close of business on November 11,…NasdaqPCAR, ABT, TXN, MCD
- Notable ETF Inflow Detected - IHI, ABT, ISRG, SYKLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected…NasdaqIHI, ABT, ISRG, SYK
- Here's What Is Shaping Abbott's Diagnostics GrowthABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.NasdaqABT, DHR, QDEL
- IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins ImproveIDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.NasdaqIDXX, ABT, LH
- Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade)Seeking Alpha
- Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-TermSeeking Alpha
- Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.NasdaqEW, ABT, BSX
- Abbott: Bear Trap Over, With Richer Return ProspectsSeeking Alpha
- Abbott Laboratories: Pick Up This Dividend King Deal NowSeeking Alpha
- Abbott Laboratories (ABT) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)Seeking Alpha